SCHEMBL718523

SCHEMBL718523

CC(=O)Oc1ccc(CCc2cc(OC(C)=O)cc(OC(C)=O)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
LMNA P02545 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
KMT2A Q03164 2/20 0.56
KDM4E B2RXH2 1/20 0.56
MEN1 O00255 1/20 0.56
TTR P02766 1/20 0.56
TP53 P04637 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP4F2 P78329 1/20 0.50
CYP4A11 Q02928 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
POLB P06746 2/20 0.48
PKM P14618 1/20 0.48
PTGS2 P35354 1/20 0.48
CALM1 P0DP23 1/20 0.47
ELANE P08246 1/20 0.47
THRB P10828 1/20 0.46
CYP19A1 P11511 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9081470 0.92 LMNA (0.61) MAPTLMNASMN1; SMN2KMT2AKDM4E
SCHEMBL10183039 0.90 CYP4F2 (0.58) MAPTLMNASMN1; SMN2KMT2AKDM4E
SCHEMBL13252213 0.90 LMNA (0.56) MAPTLMNASMN1; SMN2KMT2AKDM4E
SCHEMBL10148975 0.89 LMNA (0.60) MAPTLMNASMN1; SMN2KMT2AKDM4E
SCHEMBL23966248 0.87 CALM1 (0.56) MAPTLMNASMN1; SMN2KMT2AKDM4E
SCHEMBL10183554 0.87 LMNA (0.58) MAPTLMNASMN1; SMN2KMT2AKDM4E
SCHEMBL10149033 0.87 SMN1; SMN2 (0.55) MAPTLMNASMN1; SMN2KMT2AKDM4E
SCHEMBL715236 0.86 LMNA (0.54) MAPTLMNASMN1; SMN2KMT2AKDM4E
SCHEMBL717987 0.85 NPC1 (0.65) MAPTLMNASMN1; SMN2KMT2ANPC1
SCHEMBL10182922 0.84 PTGS2 (0.49) MAPTLMNASMN1; SMN2KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200188878-A1 MOLECULARLY IMPRINTED POLYMERS MONASH UNIVERSITY (AU) 2020-06-18 US disclosed
US-20200188878-A1 MOLECULARLY IMPRINTED POLYMERS MONASH UNIVERSITY (AU) 2020-06-18 US disclosed
US-9572815-B2 Methods and compositions of p27KIP1 transcriptional modulators ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2017-02-21 US disclosed
US-20160288090-A1 MOLECULARLY IMPRINTED POLYMERS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2016-10-06 US disclosed
US-20160288090-A1 MOLECULARLY IMPRINTED POLYMERS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2016-10-06 US disclosed
US-20120052757-A1 MOLECULARLY IMPRINTED POLYMERS MONASH UNIVERSITY (AU) 2012-03-01 US disclosed
US-20120052757-A1 MOLECULARLY IMPRINTED POLYMERS MONASH UNIVERSITY (AU) 2012-03-01 US disclosed
EP-2391658-A1 MOLECULARLY IMPRINTED POLYMERS Commonwealth Scientific and Industrial Research Organisation (AU) 2011-12-07 EP disclosed
WO-2010085851-A1 MOLECULARLY IMPRINTED POLYMERS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2010-08-05 WO disclosed
WO-2010085851-A1 MOLECULARLY IMPRINTED POLYMERS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160288090-A1 MOLECULARLY IMPRINTED POLYMERS IPMK, MPI, PIM3 MAPT 3368/4885LMNA 3479/4885SMN1; SMN2 3871/4885
US-20120052757-A1 MOLECULARLY IMPRINTED POLYMERS IPMK, MPI, PIM3 MAPT 3368/4885LMNA 3479/4885SMN1; SMN2 3871/4885
US-20200188878-A1 MOLECULARLY IMPRINTED POLYMERS IPMK, MPI, PIM3 MAPT 3368/4885LMNA 3479/4885SMN1; SMN2 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.